<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-141484</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Safety of daptomycin in patients with renal impairment</dc:title>
<dc:description xml:lang="en">Daptomycin is a lipopeptide bactericidal antimicrobial indicated in the treatment of skin and soft tissue infections (SSTI), Staphylococcus aureus-related right-sided infective endocarditis (RIE) and bacteremia secondary to these infections. The recommended dosage in patients with previous renal impairment is 4 mg/kg/48 hours in SSTI. There are no data published for SSTI and RIE followed by bacteremia. Based on pharmacokinetic models, the recommended dosage in patients under hemodialysis is 4 mg/kg after dialysis. The present article aims to review of the latest published data on daptomycin use in patients with renal impairment and to relate these findings to preliminary data from the EUCORE registry in Spain (AU)</dc:description>
<dc:creator>Azanza, José Ramón</dc:creator>
<dc:creator>Quetglas, Emilio G</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La daptomicina es un antibiótico bactericida perteneciente a la familia de los lipopéptidos que está indicado en el tratamiento de infecciones de piel y tejidos blandos (IPPB), endocarditis infecciosa derecha (EID) por S. aureus y en bacteriemias por S. aureus secundarias a las anteriores. La recomendación posológica en pacientes con alteración previa de la función renal es de 4 mg/kg/48 h en IPPB y no existen datos en pacientes con IPPB y EID con bacteriemia. La dosis recomendada en pacientes en hemodiálisis, basada en modelos farmacocinéticos, es de 4 mg/kg posdiálisis. El objetivo del presente artículo es la revisión de los últimos datos publicados a este respecto, relacionándolos con los resultados preliminares del registro EUCORE en el ámbito nacional (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);135(supl.3): 55-59, dic. 2010. tab</dc:source>
<dc:identifier>ibc-141484</dc:identifier>
<dc:title xml:lang="es">Seguridad de daptomicina en pacientes con insuficiencia renal</dc:title>
<dc:subject>^d28905^s22083</dc:subject>
<dc:subject>^d626^s22068</dc:subject>
<dc:subject>^d28611</dc:subject>
<dc:subject>^d7840^s22021</dc:subject>
<dc:subject>^d29504</dc:subject>
<dc:subject>^d29407</dc:subject>
<dc:subject>^d7840^s22044</dc:subject>
<dc:subject>^d7851^s22067</dc:subject>
<dc:subject>^d13590^s22057</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d626^s22020</dc:subject>
<dc:subject>^d31518^s22079</dc:subject>
<dc:subject>^d911^s22079</dc:subject>
<dc:subject>^d911^s22073</dc:subject>
<dc:subject>^d28634^s22083</dc:subject>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d4778^s22057</dc:subject>
<dc:subject>^d32025^s22057</dc:subject>
<dc:subject>^d30071^s22057</dc:subject>
<dc:subject>^d4778^s22012</dc:subject>
<dc:subject>^d32025^s22012</dc:subject>
<dc:subject>^d31518^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d30241^s22057</dc:subject>
<dc:subject>^d23311</dc:subject>
<dc:subject>^d30241^s22012</dc:subject>
<dc:subject>^d7851^s22012</dc:subject>
<dc:subject>^d9327^s22036</dc:subject>
<dc:subject>^d911^s22000</dc:subject>
<dc:subject>^d31518^s22000</dc:subject>
<dc:subject>^d841</dc:subject>
<dc:subject>^d31518^s22020</dc:subject>
<dc:subject>^d911^s22020</dc:subject>
<dc:subject>^d27794^s22083</dc:subject>
<dc:type>article</dc:type>
<dc:date>201012</dc:date>
</metadata>
</record>
</ibecs-document>
